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therapy (biologic/apremilast), the extent of treatment failure and its association with
reduced physical functioning, health related quality of life (HRQoL) and work
productivity and activity impairment (WPAI).
Methods
PsA patients under routine care and their treating physicians provided demographics,
current therapy, reasons for switching, duration of 1st therapy, HRQoL, HAQ-DI and
WPAI. Current immunomodulatory therapy was determined as ‘failing’ if, after ≥3
months, physician-rated disease severity had worsened, remained severe, was
‘unstable/deteriorating’, or they were dissatisfied with disease control and/or did not
consider treatment a ‘success’.
Results
Included were 3,714 PsA patients; 1,455 (40.6%) had never received
immunomodulatory therapy; 1796 (50.1%) had ever received 1 immunomodulatory
therapy and 331 (9.2%) ≥1. Lack of efficacy with 1st immunomodulatory therapy was
the most common reason for switching; patients whose physicians indicated ‘primary
lack of efficacy’ as the reason, switched after a mean of 9.4 months. Patients currently
failing immunomodulator therapies (n=246) had poorer HRQoL compared with
treatment success (n=1,472) measured by EQ-5D-3L (0.60 vs 0.77%; P<0.0001); SF-
36 PCS (40.8% vs 46.1%; P<0.0001) MCS (41.1% vs 45.3%; P<0.0001). Physical
functioning, activity and work productivity were also more impaired (HAQ-DI: 0.88 vs
0.56; activity impairment: 46.7% vs 29.7%; overall work impairment: 35.4% vs 26.1%;
all P<0.0001).
Conclusions
Poor treatment response in PsA is associated with substantial negative patient impact.
In cases of primary treatment failure, timely switching is needed.
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Abstract 
Objective: There are limited data on therapy selection and switching in psoriatic arthritis 
(PsA). This 18 country, real-world study assessed use and switching of immunomodulatory 
therapy (biologic/apremilast), the extent of treatment failure and its association with reduced 
physical functioning, health related quality of life (HRQoL) and work productivity and activity 
impairment (WPAI). 
Methods: PsA patients under routine care and their treating physicians provided 
demographics, current therapy, reasons for switching, duration of 1st therapy, HRQoL, HAQ-
DI and WPAI. Current immunomodulatory therapy was determined as ‘failing’ if, after ≥3 
months, physician-rated disease severity had worsened, remained severe, was 
‘unstable/deteriorating’, or they were dissatisfied with disease control and/or did not consider 
treatment a ‘success’. 
Results: Included were 3,714 PsA patients; 1,455 (40.6%) had never received 
immunomodulatory therapy; 1796 (50.1%) had ever received 1 immunomodulatory therapy 
and 331 (9.2%) ≥1. Lack of efficacy with 1st immunomodulatory therapy was the most common 
reason for switching; patients whose physicians indicated ‘primary lack of efficacy’ as the 
reason, switched after a mean of 9.4 months. Patients currently failing immunomodulator 
therapies (n=246) had poorer HRQoL compared with treatment success (n=1,472) measured 
by EQ-5D-3L (0.60 vs 0.77%; P<0.0001); SF-36 PCS (40.8% vs 46.1%; P<0.0001) MCS 
(41.1% vs 45.3%; P<0.0001). Physical functioning, activity and work productivity were also 
more impaired (HAQ-DI: 0.88 vs 0.56; activity impairment: 46.7% vs 29.7%; overall work 
impairment: 35.4% vs 26.1%; all P<0.0001). 
Conclusions: Poor treatment response in PsA is associated with substantial negative patient 
impact. In cases of primary treatment failure, timely switching is needed. 
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Introduction 
Psoriatic arthritis (PsA) is a multifaceted systemic chronic inflammatory disease with diverse 
features, varied outcomes and disease course, which affects skin and joints simultaneously 
[1-4]. The prevalence of psoriatic arthritis (PsA) varies by country, from 0.001% adults in Japan 
to 0.42% in Italy, and 0.16% in the USA, and is seen in up to 40% of psoriasis patients [1-4]. 
Patients with PsA experience pain, stiffness, enthesitis, swelling and tenderness of the joints, 
with 40-60% of patients developing erosive joint disease leading to impaired articular 
functioning and higher mortality [1,2]. These symptoms have a detrimental effect on social 
relationships, quality of life and mortality as well as burdening the patient and society with 
impaired ability to work and substantial healthcare costs [1,5].  
Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) including sulfasalazine 
and methotrexate are widely used in the treatment of PsA [6]. However, advances in 
understanding PsA pathogenesis, especially the role of T cells and cytokines, have led to a 
range of immunomodulatory treatments for PsA.  The therapeutic armamentarium now also 
includes biologic DMARDs (bDMARDs) such as tumor necrosis factor inhibitors (TNFis), anti-
interleukin (IL)-12/23 ustekinumab, anti-IL-17A secukinumab and ixekizumab; and abatacept. 
Targeted synthetic DMARDs (tsDMARD) include phosphodiesterase-4 (PDE-4) inhibitor 
apremilast and janus kinase inhibitor (JAKi) tofacitinib [7-11]. 
The choice of first line therapy, and which treatment to switch to in the event of first-line 
treatment failure, is well described in several recent treatment guidelines. The American 
College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) most recent 
guideline for treating PsA recommends TNFi as 1st-line treatment for active PsA [12]. If a 
TNFi is not an option, conventional DMARDs (cDMARDs) are preferable to other biologics. 
Methotrexate is preferable to NSAID, and anti-IL17 is preferable to an IL-12/23 [12]. If PsA is 
still active after the change, switching to anti-IL-17 should be the next step rather than a 
cDMARD or other biologic. If PsA continues to be active, switching to  an anti-IL12/23 rather 
than cDMARD, abatacept or tofacitinib is recommended [12]. The most recent GRAPPA and 
EULAR recommendations also prefer switching to a bDMARD for patients with active PsA 
despite cDMARD treatment, usually TNFi, or anti-12/23 or anti-IL17 if TNFi is not appropriate, 
or apremilast if a bDMARD is inappropriate [13,14]. EULAR recommends switching TNFi if 
target is not achieved within 3-6 months [14]. 
The aim of this large multi-national study was to describe the use of immunomodulatory 
therapy in PsA patients using real-world data, and assess treatment switching and failure 
rates, as well as the association between treatment failure and reduced physical functioning, 
quality of life and work capability.  
Materials and Methods 
Data source 
This was an analysis of data drawn from the Adelphi PsA Disease Specific Program (DSP) 
conducted between 2015 - 2016 in 18 countries: North America (USA, Canada), Latin 
America, (LatAm, covering Brazil, Mexico), EU5 (Europe, covering France, Germany, Italy, 
Spain, UK), Asia Pacific, (APAC, covering Japan, Malaysia, South Korea, Taiwan, Australia) 
and Turkey & Middle East, (T&ME, covering Egypt, Saudi Arabia, United Arab Emirates) 
regions [15].  DSPs are large, point-in-time surveys collecting evidence of real-world clinical 
practice, designed to identify current disease management and patient and physician reported 
disease impact. 
Physicians included in the survey were instructed to complete a pre-specified questionnaire 
for the next 1 – 8 (variable by country) consecutive patients with active PsA who visited for 
routine care. Physician-reported questionnaires included detailed questions on patient 
demographics, clinical assessments, medication use and treatment history. Each patient with 
a physician-completed questionnaire was invited to fill out a patient-reported form after 
providing informed consent. Patients completed their forms independently from physicians, 
returning them in sealed envelopes to ensure confidentiality. 
 The Rheumatology DSPs were conducted in accordance with the relevant legislation at time 
of data collection, including US Health Insurance Portability and Accountability Act 1996 
(HIPAA; www.hhs.gov/ocr/privacy/),[16] and Health Information Technology for Economic and 
Clinical Health Act legislation [17]. The DSP is a market research project and complies with 
all relevant market research guidelines and legal obligations.  Data were collected according 
to European Pharmaceutical Marketing Research Association guidelines and thus did not 
require ethics committee approvals [18]. Namely the DSP is non-interventional and employs 
solely retrospective data collection, and no identifiable protected health information was 
extracted during the course of the study.  
Participating physicians and patients 
Rheumatologists (and orthopedists and internists in Japan) and dermatologists were eligible 
to participate if they had worked ≥3 years’ as a physician, and had qualified between 1979-
2012, and were responsible for treatment decisions.  Rheumatologists were responsible for 
treatment decisions of axial SpA and PsA patients and Dermatologists were responsible for 
treatment decisions of PsA patients. 
Patients were eligible for inclusion if aged ≥18 years, with a physician-confirmed diagnosis of 
PsA, not currently involved in a clinical trial. There were no restrictions according to 
treatments, clinical features such as disease activity/severity or demographics.  
There were no restrictions according to treatments or clinical features such as disease 
activity/severity or demographics.  
Defining ‘treatment switching’ 
 ‘Treatment switching’ was defined as progressing from a first immunomodulator therapy to a 
second therapy of the same or different class. Physicians reported reasons for switching from 
a list of choices. Reasons for switch included factors associated with lack of initial or ongoing 
efficacy, failure to control (specific) symptoms, patient change (improvement, worsening), 
intolerability, issues associated with treatment administration, patient preference, 
administrative reasons including formulary requirements and physician preference for an 
alternative therapy. The full list is shown in Supplementary Fig. 1.  
Defining ‘failing’ and ‘success’ treatment groups 
Patients were categorized as ‘failing to respond” on current immunomodulatory treatment if, 
>3 months after initiating therapy with TNFi, apremilast or ustekinumab, ≥ 1 of the following 
criteria, assessed by the treating physician, were met: disease severity (reported as mild, 
moderate, severe PsA) had worsened or remained severe; disease activity (reported as 
improving, stable, unstable, deteriorating) was unstable or deteriorating; physicians reported 
dissatisfaction with current control of PsA; or reported they did not consider the patient's 
current treatment regimen a ‘success’. Any patient not considered in the ‘failing to respond’ 
group was included as a ‘treatment success’.  
Patient reported outcomes 
Patient-reported forms included validated instruments including the Health Assessment 
Questionnaire – Disability Index (HAQ-DI)[19], 5-dimension EuroQoL (EQ-5D-3L),[20] Medical 
Outcomes Study Short-Form Health Survey version 2 (SF-36v2),[21] and the Work 
Productivity and Activity Impairment (WPAI-GH)[22] questionnaire.  
Statistical analyses 
Patient characteristics were descriptively analysed for the total study sample at global and 
regional levels (North America, LatAm, EU5, APAC, T&ME) by demographics and underlying 
patient condition (including age, gender, BMI, and BSA affected by psoriasis), number of 
immunomodulators received, reasons for switching from 1st to 2nd agent, duration patients 
remained on 1st therapy and overall rates of patients failing to respond to immunomodulator 
therapy and according to line of therapy.  
Categorical variables were described by counts and proportions of respondents and 
continuous numerical variables were described by their medians, means and standard 
deviations. Pearson’s ² test assessed differences in failure rates by lines of therapy.  
Linear regression analyses were performed for EQ5D, SF-36 PCS and MCS, and WPAI.  The 
independent variable was treatment response (failing to respond or success), and differences 
in age, gender, BMI, smoking status, time since symptom onset and region were controlled 
for. Predicted values for all outcomes were subsequently stratified by failure or success whilst 
all other variables were fixed at their means.  
All analyses used Stata Statistical Software: Release 15 (StataCorp LP, College Station, TX). 
Results 
Patients and physicians 
A total of 949 physicians from 18 countries (North America, n=155; LatAm, n=85; EU5, n=450; 
APAC, n=127; T&ME, n=132) and 3,714 PsA patients (North America, n=707; LatAm, n=281; 
EU5, n=1820; APAC, n=543; T&ME, n=363) from the DSP were eligible for inclusion in this 
analysis; in total 48.2% provided by Rheumatologists (including Orthopaedic Internal Medicine 
in Japan), 51.8% by Dermatologists. 
Key patient demographic and disease characteristics are summarised in Table 1. Patient 
characteristics including mean age, BMI, time since diagnosis and HAQ-DI were comparable 
for most regions with some exceptions. In T&ME, median time since diagnosis and symptom 
onset was less than other regions at 0.5 year and 1 year compared to 2-3 years and 4-5 years 
respectively. HAQ-DI was higher for T&ME than for other regions. In addition, there were less 
patients with mild disease severity and more with moderate disease severity as reported by 
the treating physician than for other regions. Among patients with psoriasis, those in APAC 
had the highest proportion of psoriasis affected BSA, with a mean of 13.6% compared to 8.5%-
11.3% in other regions.  
Of 3,714 patients with PsA, 1,856 patients completed the voluntary questionnaires, including 
EQ-5D (n=1,809), SF-36 (n=1,699), and WPAI (n=1,779). Patient reported outcomes were 
comparable across most regions, other than T&ME where they were notably poorer than other 
regions.  
Use of immunomodulators  
Of 3,582 patients with complete treatment data, 1,455 (40.6%) had never received 
immunomodulators, 1,796 (50.1%) were receiving the 1st immunomodulator, 243 (6.8%) the 
2nd immunomodulator and 88 (2.5%) the 3rd or later immunomodulator (Table 2). Of 2221 
globally treated patients (including 94 with incomplete data as to total number of 
immunomodulators used), the majority received TNFi (84.5%); true across all regions included 
in this study (Table 2). 
Immunomodulator treatment switching 
Supplementary Fig. 1 presents the data for reasons for switching from 1st to 2nd 
immunomodulatory therapy. Physicians selected reasons for switching from a pre-specified 
list for 304 PsA patients who had received >1 immunomodulator and reason for switch was 
known. Responses that explicitly indicated lack of efficacy were selected for more than two 
thirds of patients who switched therapy; “secondary lack of efficacy (loss of response over 
time)” was selected for 134 (44.1%) and “primary lack of efficacy (initial non-response)” for 69 
(22.7%). Other selected reasons included “condition worsened” in 114 (37.5%), “lack of pain 
relief” in 58 (19.1%), “remission not maintained” in 57 (18.8%) and “remission was not induced” 
in 50 (16.4%).  
For the 58 whose physicians reported that primary lack of efficacy was the reason for 
immunomodulator switch, mean duration of initial therapy was 9.4 months (standard deviation 
11.9 months) before switching with a maximum time to switch of 84 months (Table 2). 
Immunomodulator treatment response 
Based on the definition provided, 246 (14.3%) of patients receiving immunomodulator were 
currently failing to respond. Rates of current treatment failure increased significantly with 
successive immunomodulators. Globally 12.7% of patients currently receiving 1st therapy were 
failing current treatment, this doubled to 26.6% for patients currently receiving their 3rd or later 
therapy (P=0.0022) (Fig. 1). In North America and LatAm, rates of failure followed this trend, 
11.8% and 14.9% of patients currently failing 1st therapy increased to 16.7% and 50.0% at 3rd 
respectively (both P=NS).  In Europe and APAC 12.8% and 12.1% of patients on 1st therapy 
were reportedly failing which increased to 33.3% (P=0.0030) and 20.0% (P=NS) failing 3rd 
respectively. In T&ME, 11.9% patients on 1st therapy were failing; data are only available for 
2 patients who had switched to a 2nd therapy both of whom were failing (Fig. 1).  
Patient demographics by therapy success and failure 
Patient characteristics were similar between success and failing groups across all regions with 
some exceptions in the APAC region; mean BMI was significantly higher (26.1 vs 24.7, 
P=0.0309), and time since diagnosis significantly shorter (3.1 vs 5.1, P=0.0406) for those who 
were failing therapy (Table 3). Globally, BSA affected by psoriasis was significantly higher in 
patients failing therapy (14.5 vs 7.4, P<0.0001).  This pattern was observed for every region 
apart from APAC (Table 3). Globally, ESR and CRP levels were significantly higher in patients 
failing treatment: ESR in North America, EU5, APAC and T&ME; CRP in North America, EU5 
and T&ME and numerically higher in the APAC region. ESR and CRP data were too limited in 
LatAm to be meaningful (Table 3). 
Association of failing treatment with HRQoL and WPAI 
Linear regression analysis, controlling for age, gender, smoking status, BMI, time since onset 
of symptoms and region, confirmed that failing treatment was significantly associated across 
all regions with lower EQ-5D and HAQ-DI scores (Fig. 2a and b); and worse SF-36 PCS and 
MCS scores (Fig. 2c). We also observed that patients who were failing treatment reported 
significantly worse outcomes on all the individual SF-36 domains (Fig. 3).  
Adjusted WPAI scores were higher in patients failing treatment indicating more work 
impairment, time missed at work, impairment while working and impairment in daily activities 
than in patients for whom therapy was not failing (Fig. 2d).  
  
Discussion 
This analysis of real-world data on immunomodulator use in patients with PsA from a large 
multi-national survey demonstrates that current therapies do not consistently deliver sustained 
efficacy, evidenced by high rates of primary and secondary lack of efficacy to the 1st treatment 
(predominantly TNFi), resulting in patients switching therapies, consistent with previous 
reports [23,24].  
Time to switch therapy due to lack of efficacy may be longer than recommended by EULAR 
treatment guidelines [6]. In cases where physicians reported switching from 1st to 2nd 
immunomodulatory therapy was due to primary lack of efficacy, time to switch to an alternative 
therapy occurred at a mean of 9.4 months. An observational study based on the nationwide 
DANBIO registry of 1,422 patients with PsA initiating TNFis demonstrated that 39% switched 
to a 2nd TNFi over a median of 2.3 years follow-up and a US study conducted over 4 years 
reported 22.9% of patients switched biologic therapy [25]. However, in this global analysis of 
3,582 patients, at the time of data collection 6.8% had received a 2nd and 2.5% a 3rd therapy, 
with 9.4% and 4.9% receiving a 2nd and 3rd therapy in the US respectively. These differing 
rates are a result of our analysis being based on a cross-section of patients with differing 
disease durations, rather than a longitudinal study of patients over time [26,27]. 
The likelihood of patients failing their current treatment was higher with each successive 
therapy. These data are consistent with other studies, including a metanalysis of observational 
studies published between 2007 and 2015 of patients with PsA who have failed at least one 
prior TNFi. Compared to patients with no TNFi treatment, TNFi in the second-line and 
subsequent lines demonstrated statistical improvement in PsA outcomes, however responses 
to first-line TNFi demonstrated statistically greater improvements than second- and third-line 
TNFi. No improvement was found at 24 weeks for fourth-line TNFi compared to second-line 
treatment [28]. In addition, studies reviewed by Merola et al indicate that treatment responses 
and length of treatment survival decrease in patients receiving a 2nd or 3rd TNFi [29-32].  
Recently, large-scale randomized controlled trials of biologics and targeted small molecules 
demonstrated ACR20/50/70 and PASI-75 responses that were significantly improved versus 
placebo in patients who had failed one or more TNFi [32,11,33,34]. As a result, both updated 
GRAPPA and EULAR guidelines recommend switching to alternative biologics including those 
with different modes of action after TNFi failure [13,14]; ACR-NPF guidelines specify switching 
to an anti-IL17 if PsA remains active after failure of a TNFi, followed by an anti-IL12/23 if PsA 
continues to be active [12].   
The current study was performed before the market authorization of recently approved 
immunomodulatory agents for PsA, however the real-world clinical impact of their availability 
would be expected to impact treatment switching. 
Our analyses demonstrate that failure of immunomodulator therapy is associated with 
significantly poorer patient reported HRQoL by EQ-5D and SF-36, physical functioning by 
HAQ-DI and performance of daily activities and work by WPAI. We observed that the T&ME 
cohort had notably worse disease activity and patient reported outcomes compared with other 
regions. We hypothesize that this may be due to shorter disease duration and lower use of 
bDMARDs in this region which may have led to poorer disease control compared with other 
regions. 
 
Although PsA has been reported to negatively impact HRQOL [35-40],  and several studies 
report increased absenteeism and presenteeism in patients with PsA [41-43,36] to the best of 
our knowledge, this is the first real-world study to compare HRQoL and work productivity in 
PsA patients failing treatment , with those whose treatment is considered to working effectively 
(i.e. not failing).  
A major strength of this study is that it presents real-world data from a large number of PsA 
patients around the world, providing insight into real rates of treatment failure and reasons for 
treatment switching. Several potential limitations of this Adelphi PsA DSP should be 
considered. A primary limitation of the analysis is that the source data is a point-in time survey 
and does not capture the exact timepoint at which patients fail to respond to therapy, therefore 
it was necessary to rely on physician reported reasons for switching therapy to identify the 
sub-set who failed to respond. Other limitations relate to cross-sectional study design, and 
selection of patients based on those who agreed to participate.  Physician reported disease 
activity/severity can reflect individual physician bias.  Similarly, regional differences in patient 
characteristics, treatment practices and physician expertise may have influenced findings in 
this cross-sectional study. Recall bias is a common limitation of surveys, however as data was 
collected at the time of patients’ appointments, the likelihood of recall bias is reduced. Finally, 
although the level of knowledge and management strategies for PsA treatment may differ 
between Rheumatologists and Dermatologists, thereby affecting treatment satisfaction and 
clinical outcomes, differences attributable to physician specialities were not evaluated. 
In conclusion, this large multinational real-world survey in PsA patients demonstrated that lack 
of efficacy of immunomodulatory therapy was not uncommon and the predominant reason for 
treatment switching. Failure to respond was associated with significantly poorer patient 
reported HRQoL, physical functioning and work productivity. A significant proportion of 
patients who switched onto 2nd or 3rd therapy did not respond as expected, albeit the majority 
were TNFis. More regular monitoring and earlier use of appropriate therapies upon 
identification of lack of efficacy may lead to improvements in disease control and reduce 
progression leading to improved HRQoL, physical function and productivity benefits to society. 
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Figure Legends 
Fig. 1 Patients currently ‘failing’ 1st, 2nd, 3rd or later immunomodulator therapy Rates of 
failure on successive lines of immunomodulator therapy. APAC, Asia Pacific region; EU5, 
European Union 5; LatAm, Latin America, T & ME, Turkey & Middle East 
Fig. 2 EQ-5D scores (A), HAQ-DI scores (B), SF-36 scores (C) and WPAI (D) for 
patients failing immunomodulator therapy vs. immunomodulator therapy success 
Results are adjusted for age, gender, smoking status, BMI, time since onset of symptoms 
and region. ABS, absenteeism; ACT, activity impairment; APAC, Asia Pacific region; EU5, 
European Union 5; LatAm, Latin America; O, overall work impairment; PRES, presenteeism; 
SD, standard deviation; T & ME, Turkey & Middle East. SF-PCS, P<0.0001; SF-MCS, 
P=0.0010; overall work impairment, P=0.0727; presenteeism, P=0.0212; absenteeism, 
P=0.3932; activity impairment, P<0.0001 
Fig. 3 Spydergram of adjusted SF-36 domain scores for patients failing 
immunomodulator therapy vs. immunomodulator therapy success Results are adjusted 
for age, gender, smoking status, BMI, time since onset of symptoms and region 
Supplementary Fig. 1 Reasons for switching from 1st to 2nd TNFi (n=304) Physician 
reported reasons given for patient switching from 1st to 2nd line immunomodulator therapy. * 
Secondary lack of efficacy (loss of response over time); ‡ I wanted to use a bDMARD that 
can be used in combination; † I wanted to use bDMARD that can be used as a 
monotherapy. bDMARD: biologic Disease Modifying Anti-Rheumatic drugs; MOA, Mode of 
action 
 
Table 1. Patient Characteristics 
 
Characteristic 
All 
(n=3714) 
North 
America 
(n=707) 
LatAm 
(n=281) 
EU5 
(n=1820) 
APAC 
(n=543) 
T & ME  
(n=363) 
Age, years  (n=3710) (n=707) (n=281) (n=1820) (n=539) (n=363) 
Median 47.0 49.0 48.0 48.0 51.0 40.0 
IQR 39.0, 57.0 39.0, 57.0 40.0, 58.0 40.0, 58.0 41.0, 61.0 35.0, 43.0 
Mean (SD) 48.2 (12.5) 48.1 (12.6) 49.1 (12.1) 48.9 (12.4) 51.5 (13.5) 39.7 (7.3) 
Male, n (%) 1916 (51.6) 345 (48.8) 141 (50.2) 956 (52.5) 320 (59.0) 154 (42.4) 
BMI, kg/m2 (n=3708) (n=707) (n=281) (n=1820) (n=539) (n=361) 
Median 25.7 26.7 26.0 25.4 23.9 26.1 
IQR 23.3, 28.4 24.3, 30.4 23.9, 28.4 23.3, 28.0 21.7, 27.0 24.6, 28.4 
Mean (SD) 26.4 (4.7) 28.0 (5.6) 26.4 (4.0) 26.1 (4.3) 25.0 (4.9) 26.8 (3.7) 
Time since symptom onset 
(years) 
(n=2943) (n=542) (n=262) (n=1405) (n=390) (n=344) 
Median 4.0 4.0 4.0 5.0 5.0 1.0 
IQR 2.0, 8.0 2.0, 10.0 1.8, 8.0 2.0, 9.0 2.0, 10.0 1.0, 2.0 
Mean (SD) 6.3 (7.4) 6.8 (7.1) 6.3 (6.7) 7.0 (7.9) 7.2 (7.7) 1.9 (2.0) 
Time since diagnosis 
(years) 
(n=3210) (n=583) (n=267) (n=1597) (n=412) (n=351) 
Median 3.0 3.0 2.0 3.0 3.0 0.5 
IQR 1.0, 6.0 1.0, 6.0 0.8, 5.0 1.4, 7.0 1.0, 7.0 0.1, 1.0 
Mean (SD) 4.7 (6.0) 4.9 (5.7) 4.4 (6.0) 5.5 (6.5) 5.1 (5.5) 1.0 (1.5) 
Current severity (physician 
reported), n (%) 
      
Mild 2378 (64.1) 478 (67.6) 183 (65.1) 1159 (63.7) 379 (70.1) 179 (49.6) 
Moderate 1162 (31.3) 208 (29.4) 80 (28.5) 568 (31.2) 149 (27.5) 157(43.5) 
Severe 170 (4.6) 21 (3.0) 18 (6.4) 93 (5.1) 13 (2.4) 25 (6.9) 
PsA with psoriasis, n % 3512 (94.6) 677 (95.8) 261 (92.9) 1727 (94.9) 497 (91.9) 350 (96.4) 
% BSA currently affected 
by psoriasis 
(n=2731) (n=562) (n=259) (n=1172) (n=400) (n=338) 
Median 5.0  5.0 1.8 7.0 8.0 6.0 
IQR 2.0, 15.0 2.0, 15.0 0.0, 11.8 3.0, 15.0 2.0, 20.0 3.0, 12.0 
Mean (SD) 11.1 (13.4) 11.3 (14.2) 8.5 (14.2) 11.2 (12.5) 13.6 (15.9) 9.5 (9.9) 
EQ-5D utility score (n=1809) (n=371) (n=217) (n=742) (n=265) (n=214) 
Median 0.8 0.83 0.77 0.84 0.85 0.08 
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IQR 0.59, 1.00 0.77, 1.00 0.59, 1.00 0.68, 1.00 0.73, 1.00 -0.02, 0.52 
Mean (SD) 0.72 (0.32) 0.84 (0.17) 0.73 (0.29) 0.76 (0.28) 0.84 (0.19) 0.18 (0.32) 
SF36 PCS (n=1657) (n=382) (n=69) (n=728) (n=263) (n=215) 
Median 44.3 48.9 39.6 44.7 47.8 37.4 
IQR 37.0, 52.0 40.2, 54.2 34.1, 44.1 36.9, 52.1 41.9, 52.8 33.6, 42.2 
Mean (SD) 44.1 (9.2) 46.9 (9.2) 40.0 (7.3) 43.9 (9.6) 46.6 (8.2) 37.9 (6.0) 
SF36 MCS (n=1657) (n=382) (n=69) (n=728) (n=263) (n=215) 
Median 44.5 53.2 36.5 45.6 44.8 38.0 
IQR 37.0, 53.0 42.9, 58.0 35.0, 41.6 37.0, 51.7 37.4, 52.2 34.2, 41.3 
Mean (SD) 44.4 (10.4) 50.1 (9.9) 38.1 (8.0) 44 (10.7) 44.6 (9.4) 37.5 (5.7) 
HAQ-DI (n=1668) (n=383) (n=69) (n=735) (n=266) (n=215) 
Median 0.5 0.13 0.88 0.5 0.19 1.5 
IQR 0.00, 1.13 0.00, 0.50 0.38, 1.13 0.00, 1.14 0.00, 0.63 1.13, 1.63 
Mean (SD) 0.67 (0.70) 0.36 (0.48) 0.89 (0.64) 0.70 (0.76) 0.40 (0.52) 1.37 (0.45) 
WPAI, overall work 
impairment 
(n=886) (n=235) (n=98) (n=300) (n=135) (n=118) 
Median 20 10 20 20 20 67.6 
IQR 10.0, 50.9 0.0, 30.0 0.0, 52.6 10.0, 40.0 10.0, 30.0 63.5, 78.3 
Mean (SD) 29.2 (27.5) 17.1 (19.9) 30 (30.3) 25.2 (24.4) 24.2 (20.6) 68.7 (15.2) 
 
APAC, Asia Pacific region; BMI, body mass index; BSA, body surface area; EQ-5D, EuroQol 
5-dimensions questionnaire; EU5, European Union 5; HAQ-DI, health assessment 
questionnaire disability index ; MCS, mental component score; LatAm, Latin America; PsA, 
psoriatic arthritis; T & ME, Turkey & Middle East; PCS, physical component score; SD, 
standard deviation; SF-36, Medical Outcomes Study Short-Form (36-item) Health Survey; 
WPAI, work productivity and activity impairment questionnaire. 
 
Table 2. Treatment with immunomodulating therapies 
 All North 
America 
LatAm 
 
EU5 
 
APAC 
 
T & ME  
 
Number of immunomodulating 
therapy ever received, n (%) 
(n=3582) (n=680) (n=276) (n=1780) (n=491) (n=355) 
0 1455 (40.6) 203 (29.9) 24 (8.7) 761 (42.8) 230 (46.8) 237 (66.8) 
1 1796 (50.1) 380 (55.9) 229 (83.0) 848 (47.6) 229 (46.6) 110 (31.0) 
2 243 (6.8) 64 (9.4) 19 (6.9) 130 (7.3) 23 (4.7) 7 (2.0) 
3+ 88 (2.5) 33 (4.9) 4 (1.4) 41 (2.3) 9 (1.8) 1 (0.3) 
Current class of 
immunomodulator therapy, n 
(%) 
(n=2221) (n=504) (n=257) (n=1059) (n=276) (n=125) 
   TNFi 1877 (84.5) 355 (70.4) 254 (98.8) 924 (87.3) 238 (86.2) 106 (84.8) 
   Non-TNFi bDMARD 239 (10.8) 80 (15.9) 3 (1.2) 106 (10.0) 31 (11.2) 19 (15.2) 
   tsDMARD (oral) 105 (4.7) 69 (13.7) 0 (0.0) 29 (2.7) 7 (2.5) 0 (0.0) 
Time on 1st 
immunomodulatory therapy 
when physician recorded 
‘primary lack of efficacy’, 
months 
(n=58) (n=20) (n=2) (n=29) (n=4) (n=3) 
Mean (SD) 9.4 (11.9) 12.8 (18.8) 3.5 (3.5) 7.7 (5.7) 7.0 (3.5) 10.7 (1.2) 
Median 6.0 6.0 3.5 6.0 6.0 10.0 
Min, max 1.0, 84.0 2.0, 84.0 1.0, 6.0 1.0, 24.0 4.0, 12.0 10.0, 12.0 
IQR 4.0, 12.0 4.5, 11.0 1.0, 6.0 3.0, 12.0 5.0, 9.0 10.0, 12.0 
Patient immunomodulator therapy exposure and switching. APAC, Asia Pacific region; BMI, 
body mass index; bDMARD: biologic Disease Modifying Anti-Rheumatic drug; EU5, 
European Union 5; LatAm, Latin America; SD, standard deviation; T & ME, Turkey & Middle 
East; TNFi, Tumor Necrosis Factor inhibitor; tsDMARD, targeted synthetic Disease 
Modifying Anti-Rheumatic drug. 
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Table 3. Patient characteristics of ‘immunomodulator therapy success’ and ‘immunomodulator therapy failing’ cohorts 
 All North America LatAm EU5 APAC T & ME  
Group 
Success 
(n=1472) 
Failing 
(n=246) 
Success 
(n=332) 
Failing 
(n=49) 
Success 
(n=159) 
Failing 
 (n=31) 
Success 
(n=747) 
Failing 
(n=130) 
Success 
(n=172) 
Failing 
(n=25) 
Success 
(n=62) 
Failing 
(n=11) 
Age, years 
Median 49.0 49.0 50.5 51.0 49.0 45.0 49.0 49.0 51.0 49.0 40.0 39.0 
IQR 41.0, 57.0 41.0, 57.0 42.0, 58.0 46.0, 59.0 41.0, 58.0 42.0, 57.0 41..0, 56.0 41.0, 58.0 41.0, 61.0 45.0, 56.0 35.0, 43.0 35.0, 44.0 
Mean (SD) 48.8 (11.6) 49.3 (12.0) 49.1 (11.8) 51.4 (12.6) 49.2 (11.6) 48.5 (11.5) 48.7 (11.3) 49.3 (12.1) 51.1 (12.8) 50.6 (10.8) 39.5 (5.9) 38.6 (5.4) 
P 0.6918 0.2225 0.7465 0.7560 0.7142 0.7452 
Male, n (%) 819 (55.6) 131 (53.3) 182 (54.8) 21 (42.9) 89 (56.0) 15 (48.4) 407 (54.5) 73 (56.2) 112 (65.1) 14 (56.0) 29 (46.8) 8 (72.7) 
P 0.4894 0.1271 0.5546 0.7748 0.3813 0.1898 
BMI, kg/m2 
Median 25.8 26.4 27.2 27.3 26.4 25.0 25.5 26.3 23.5 25.7 26.0 26.5 
IQR 23.4, 28.8 24.1, 29.4 24.8, 30.8 24.4, 34.6 24.2, 29.1 23.4, 28.1 23.3, 28.3 23.9, 29.4 21.6, 26.3 23.6, 29.1 24.9, 28.5 25.8, 27.7 
Mean (SD) 26.6 (4.8) 27.2 (5.1) 28.4 (5.8) 29.2 (6.0) 27.0 (4.2) 25.9 (4.0) 26.2 (4.3) 27.1 (5.2) 24.7 (4.7) 26.1 (4.8) 26.9 (2.5) 26.6 (1.3) 
P 0.0600 0.4942 0.1627 0.0578 0.0309 0.7402 
Time since symptom onset (years) 
n 1177 190 252 38 152 31 585 91 126 20 62 10 
Median 5.0 5.0 5.0 7.0 5.0 4.0 6.0 7.0 5.0 3.0 2.0 3.0 
IQR 3.0, 10.0 2.2, 10.0 3.0, 10.0 3.0, 12.0 3.0, 10.0 1.3, 7.0 3.0, 10.0 4.0, 15.0 2.0, 10.0 2.0, 7.5 2.0, 2.0 1.0, 4.0 
Mean (SD) 7.6 (7.2) 8.6 (8.7) 8.0 (7.4) 8.7 (6.9) 7.4 (6.9) 6.3 (8.2) 8.3 (7.6) 10.3 (9.3) 6.5 (5.4) 7.0 (9.9) 2.4 (1.6) 2.6 (1.5) 
P 0.7789 0.4084 0.1040 0.1140 0.4063 0.7294 
Time since diagnosis (years) 
n 1282 205 277 40 151 31 659 103 134 21 61 10 
Median 4.0 4.0 4.0 5.0 3.0 2.0 5.0 6.0 3.0 2.0 1.0 1.5 
IQR 2.0, 8.0 2.0, 8.0 2.0, 8.0 2.8, 10.0 2.0, 7.0 0.8, 5.0 2.5, 9.0 3.0, 10.0 2.0, 7.0 1.2, 3.0 0.8, 2.0 0.7, 3.0 
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Patients were deemed to be failing immunomodulator therapy after at least 3 months if disease severity had worsened or remained severe, 
disease activity was unstable or deteroriating, disease was not considered by physician to be controlled, nor treatment a success. Patients not 
considered to be failing immunomodulator therapy were considered to be ‘immunomodulator therapy success’. APAC, Asia Pacific region; BMI, 
body mass index; BSA, body surface area; CRP, c-reactive protein; ESR, erthyrocyte sedimentation rate; EU5, European Union 5; LatAm, Latin 
America; T & ME, Turkey & Middle East; SD, standard deviation. 
Mean (SD) 6.0 (6.1) 6.3 (6.8) 6.0 (5.8) 6.8 (5.5) 5.5 (6.2) 4.9 (8.1) 6.8 (6.4) 7.6 (7.2) 5.1 (4.9) 3.1 (3.3) 1.6 (1.6) 1.7 (1.1) 
P 0.6836 0.2577 0.1052 0.4101 0.0406 0.7275 
% BSA affected by psoriasis currently 
n 1143 179 280 38 155 30 509 80 138 20 61 11 
Median 4.0 10.0 5.0 9.0 0.2 12.0 5.0 10.0 5.0 9.5 3.0 6.0 
IQR 1.0, 10.0 5.0, 20.0 1.0, 10.0 5.0, 24.0 0.0, 7.3 1.8, 15.4 1.0, 10.0 5.0, 22.5 1.0, 10.0 5.0, 16.5 2.0, 5.0 5.0, 10.0 
Mean (SD) 7.4 (10.4) 14.5 (14.4) 7.5 (10.1) 15.3 (16.9) 5.9 (11.7) 14.2 (16.3) 6.9 (8.5) 15.1 (13.0) 11.1 (15.4) 13.2 (13.9) 6.2 (7.6) 10.5 (10.9) 
P <0.0001 0.0004 <0.0001 <0.0001 0.0832 0.0072 
ESR, mm/hr (within 3 months) 
n 547 85 95 15 10 0 324 51 63 10 55 9 
Median 12.0 23.0 16.0 23.0 11.5 - 11.0 22.0 10.0 22.0 15.0 25.0 
IQR 7.0, 20.0 15.0, 34.0 10.0, 24.0 18.0, 43.0 10.0, 13.0 - 5.0, 19.0 15.0, 34.0 6.0, 16.0 8.0, 38.0 12.0, 19.0 19.0, 32.0 
Mean (SD) 14.4 (10.4) 27.7 (20.9) 17.4 (9.7) 29.5 (20.3) 11.6 (4.5) - 13.6 (10.4) 26.9 (20.6) 13.0 (13.0) 30.4 (31.0) 16.1 (6.6) 25.7 (9.9) 
P <0.0001 0.0276 - <0.0001 0.0426 0.0050 
CRP, mg/l (within 3 months) 
n 506 82 74 12 11 0 307 52 62 10 52 8 
Median 2.6 5.0 1.8 4.3 0.7 - 4.0 6.0 0.6 1.1 1.8 5.0 
IQR 1.0, 5.4 2.4, 10.0 0.9, 3.4 2.7, 7.6 10.0, 13.0 - 2.0, 7.0 3.0, 10.5 0.2, 2.9 0.3, 3.0 1.3, 2.5 2.9, 6.5 
Mean (SD) 4.5 (5.9) 8.9 (12.9) 4.7 (8.3) 5.5 (3.7) 0.8 (1.1) - 5.4 (5.6) 9.9 (12.6) 2.5 (5.6) 5.0 (11.5) 2.3 (1.8) 12.4 (22.5) 
P <0.0001 0.0073 - 0.0004 0.8005 0.0003 
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